CTR20262059 HW-130 malignant carcinoid tumor of digestive tract Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262059 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262059 is a hot trial to watch
malignant carcinoid tumor of digestive tract is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262059 is notable because it evaluates HW-130 in a Phase 2 design sponsored by Shenzhen Neptunus Pharmaceutical Research Institute Co. Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262059 |
| Official title | 一项在晚期恶性消化道肿瘤患者中评价HW130的安全性和初步抗肿瘤疗效的IIa期临床试验 |
| Phase / status | Phase 2 / 进行中 （尚未招募） |
| Intervention | HW-130 |
| Sponsor | Shenzhen Neptunus Pharmaceutical Research Institute Co. Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 签署知情同意书至末次用药后28天（+7天）或者开始新抗肿瘤治疗前。 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of HW-130 in malignant carcinoid tumor of digestive tract.
Allocation is 随机化, masking is 开放, and the intervention model is 平行分组. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (签署知情同意书至末次用药后28天（+7天）或者开始新抗肿瘤治疗前。) — 不良事件：不良事件（AE）、严重不良事件（SAE）等各类AE，基于美国国家癌症研究所（NCI）不良事件通用术语标准第6.0版（CTCAE v6.0）评价。
- Primary endpoint (按照方案规定，筛选期、治疗期间每次访视、治疗结束后随访期。) — 实验室检查与其它相关评估：生命体征、体格检查、美国东部肿瘤协作组（ECOG）评分、临床实验室检查（血常规、血生化、凝血功能、尿常规、便常规与潜血、心肌酶）、心电图、超声心动图。
- Primary endpoint (治疗开始后至末次用药期间。) — 给药调整情况：暂停给药和永久停药等发生情况。
- Primary endpoint (治疗期间：每2个治疗周期（±1周）评估一次影像学；满6个治疗周期后改为每4个治疗周期（±1周）一次，直至疾病进展、死亡、失访、撤回知情同意、开始新的抗肿瘤治疗、申办者终止研究或试验结束。) — 肿瘤缓解：根据RECIST v1.1标准，由研究者评估的客观缓解率（ORR）、疾病控制率（DCR）、完全缓解率（CRR）、缓解持续时间（DOR）、至缓解时间（TTR）。
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: HW-130 is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Shenzhen Neptunus Pharmaceutical Research Institute Co. Ltd. is resolved to a normalized organization record in Shenzhen, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262059 provides a focused lens on malignant carcinoid tumor of digestive tract development. Its value will be determined by whether HW-130 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
